SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-079059
Filing Date
2024-06-28
Accepted
2024-06-28 16:12:03
Documents
11
Period of Report
2024-06-26
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K janx-20240626.htm   iXBRL 8-K 55438
  Complete submission text file 0000950170-24-079059.txt   178426

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT janx-20240626.xsd EX-101.SCH 28392
14 EXTRACTED XBRL INSTANCE DOCUMENT janx-20240626_htm.xml XML 5113
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 241085870
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)